Literature DB >> 16132704

Inhibition of secretory phospholipase A(2) enzyme by bilirubin: a new role as endogenous anti-inflammatory molecule.

Noor Mohamed Jameel1, Brigitte M Frey, Felix J Frey, T Veerabasappa Gowda, Bannikuppe S Vishwanath.   

Abstract

Bilirubin is a powerful antioxidant that suppresses the inflammatory process. However its interaction with proinflammatory PLA(2) enzyme is not known. Inhibition of several secretory phospholipase A(2) (sPLA(2)) enzyme activities by bilirubin was studied using (14)C-oleate labeled Escherichia coli as substrate. Bilirubin inhibits purified sPLA(2) enzyme from Vipera russellii and Naja naja venom and partially purified sPLA(2) enzymes from human ascitic fluid, pleural fluid and normal serum in a dose dependent manner. IC(50) values calculated for these enzymes ranges from 1.75 to 10.5 microM. Inflammatory human sPLA(2) enzymes are more sensitive to inhibition by bilirubin than snake venom sPLA(2)s. Inhibition of sPLA(2) activity by bilirubin is independent of calcium concentration. Increasing substrate concentration (upto 180 nmol) did not relieve the inhibition of sPLA(2) by bilirubin and it is irreversible. Bilirubin quenched the relative fluorescence intensity of sPLA(2) in a dose dependent manner in the same concentration range at which in vitro sPLA(2) inhibition was observed. In the presence of bilirubin, apparent shift in the far UV-CD spectra of sPLA(2) was observed, indicating a direct interaction with the enzyme. Inhibition of sPLA(2) induced mouse paw edema by bilirubin confirms its sPLA(2) inhibitory activity in vivo also. These findings indicate that inhibition of sPLA(2) by bilirubin is mediated by direct interaction with the enzyme and bilirubin may act as an endogenous regulator of sPLA(2) enzyme activity. Mol Cell Biochem. 2005 Aug;276(1-2):219-25.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132704     DOI: 10.1007/s11010-005-4441-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

Review 1.  New trends in mammalian non-pancreatic phospholipase A2 research.

Authors:  G Béréziat; J Etienne; M Kokkinidis; J L Olivier; P Pernas
Journal:  J Lipid Mediat       Date:  1990 May-Jul

2.  Inhibited serum phospholipase A2 activity in hyperbilirubinemia.

Authors:  M Miyashita; M Onda; T Nomura; T Matsutani; Y Tsuchiya; K Sasajima
Journal:  Hepatogastroenterology       Date:  2000 Sep-Oct

3.  Purification and characterization of a major phospholipase A2 from Russell's viper (Vipera russelli) venom.

Authors:  S Kasturi; T V Gowda
Journal:  Toxicon       Date:  1989       Impact factor: 3.033

Review 4.  Regulation and inhibition of phospholipase A2.

Authors:  J Balsinde; M A Balboa; P A Insel; E A Dennis
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

5.  Phospholipase A2-induced pleural inflammation in rats.

Authors:  B M Weichman; J W Berkenkopf; L A Marshall
Journal:  Int J Tissue React       Date:  1989

6.  Inhibition of human phospholipases A2 by cis-unsaturated fatty acids and oligomers of prostaglandin B1.

Authors:  R Franson; R Raghupathi; M Fry; J Saal; B Vishwanath; S S Ghosh; M D Rosenthal
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

Review 7.  Inflammatory effects of snake venom myotoxic phospholipases A2.

Authors:  C F P Teixeira; E C T Landucci; E Antunes; M Chacur; Y Cury
Journal:  Toxicon       Date:  2003-12-15       Impact factor: 3.033

8.  Inhibition of human non-pancreatic phospholipases A2 by retinoids and flavonoids. Mechanism of action.

Authors:  A A Fawzy; B S Vishwanath; R C Franson
Journal:  Agents Actions       Date:  1988-12

9.  Edema-inducing activity of phospholipase A2 purified from human synovial fluid and inhibition by aristolochic acid.

Authors:  B S Vishwanath; A A Fawzy; R C Franson
Journal:  Inflammation       Date:  1988-12       Impact factor: 4.092

10.  Inhibition of phospholipase A2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids.

Authors:  F F Davidson; E A Dennis; M Powell; J R Glenney
Journal:  J Biol Chem       Date:  1987-02-05       Impact factor: 5.157

View more
  8 in total

1.  Synthesis, characterization and bioactivity studies of novel 1,3,4-oxadiazole small molecule that targets basic phospholipase A2 from Vipera russelli.

Authors:  Vivek Hamse Kameshwar; Kumar J R; Babu S Priya; S Nanjunda Swamy
Journal:  Mol Cell Biochem       Date:  2016-12-07       Impact factor: 3.396

2.  Chemical modification of ascorbic acid and evaluation of its lipophilic derivatives as inhibitors of secretory phospholipase A(2) with anti-inflammatory activity.

Authors:  Riyaz Mohamed; K K Dharmappa; Shaista Tarannum; N M Jameel; S A Kannum; H S Ashrafulla; Lokanath Rai; Cletus Jmd' Souza; M A Shekhar; Bannikuppe S Vishwanath
Journal:  Mol Cell Biochem       Date:  2010-08-22       Impact factor: 3.396

3.  Association of Plasma Eicosanoid Levels With Immune, Viral, and Cognitive Outcomes in People With HIV.

Authors:  Pragney Deme; Mohammed Moniruzzaman; David Moore; Robert Heaton; Ronald Ellis; Scott Letendre; Norman Haughey
Journal:  Neurology       Date:  2022-07-18       Impact factor: 11.800

4.  Syringol isolated from Eleusine coracana (L.) Gaertn bran suppresses inflammatory response through the down-regulation of cPLA2, COX-2, IκBα, p38 and MPO signaling in sPLA2 induced mice paw oedema.

Authors:  M D Milan Gowda; K Jayachandra; Vikram Joshi; Vaddarahally N Manjuprasanna; Gotravalli V Rudresha; Devadasan Velmurugan; Raman Pachaiappan; Noor Mohamed Jameel; Bannikuppe S Vishwanath
Journal:  Inflammopharmacology       Date:  2022-05-31       Impact factor: 5.093

5.  Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation.

Authors:  Kattepura K Dharmappa; Riyaz Mohamed; Holenarasipura V Shivaprasad; Bannikuppe Sannanaik Vishwanath
Journal:  Inflammopharmacology       Date:  2009-11-06       Impact factor: 4.473

6.  Unconjugated bilirubin is associated with protection from early-life wheeze and childhood asthma.

Authors:  Kedir N Turi; Christopher McKennan; Tebeb Gebretsadik; Brittney Snyder; Christine M Seroogy; Robert F Lemanske; Edward Zoratti; Suzanne Havstad; Carole Ober; Susan Lynch; Kathyrn McCauley; Chang Yu; Daniel J Jackson; James E Gern; Tina V Hartert
Journal:  J Allergy Clin Immunol       Date:  2021-01-10       Impact factor: 14.290

7.  Identification of Traditional Chinese Medicine Constitutions and Physiological Indexes Risk Factors in Metabolic Syndrome: A Data Mining Approach.

Authors:  Yanchao Tang; Tong Zhao; Nian Huang; Wanfu Lin; Zhiying Luo; Changquan Ling
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-03       Impact factor: 2.629

Review 8.  Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2.

Authors:  Aikaterini Nikolaou; Maroula G Kokotou; Sofia Vasilakaki; George Kokotos
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-23       Impact factor: 4.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.